Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Shareholding

17 Apr 2009 15:47

RNS Number : 7804Q
ReGen Therapeutics PLC
17 April 2009
 



17th April 2009

REGEN THERAPEUTICS PLC 

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

 

2. Reason for the notification:

An event changing the break down of voting rights 

 

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

 

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd

 

5. Date of the transaction and date on which the threshold is crossed or reached (v):

15th April 2009

 

6. Date on which issued notified:

17th April 2009

 

7. Threshold(s) that is/are crossed or reached:

11% to 10%

 

8. Notified details 

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB00B28XMY25 Situation Previous to the triggering transaction (vi) – Number of Shares 2,465,917 Number of Voting Rights (viii) 2,465,917 Resulting situation after the triggering transaction (viii) – Number of Shares 2,465,917 Number of Voting Rights – Direct (x) N/A Number of Voting Rights – Indirect (xi) 2,465,917 % of voting rights – Direct N/A % of voting rights – Indirect 10.85 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of financial instrument N/A Expiration date (xiii) N/A Exercise/Conversion Period/Date (xiv) N/A Number of voting rights that may be acquired if the instrument is exercised/converted N/A % of voting rights N/A Total (A+B) Number of voting rights 2,465,917 % of voting rights 10.85

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are

effectively held, if applicable (xv): Barclays Stockbrokers Ltd

Proxy Voting:

 

10. Name of the proxy holder: N/A

 

11. Number of voting rights proxy holder will cease to hold: N/A

 

12. Date on which proxy holder will cease to hold voting rights: N/A

 

13. Additional information:   N/A

 

14. Contact name: Geoff Smith

 

15. Contact telephone number: 0207 116 2913

For further information:

For further information, please contact:Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLIRMITMMJBBFL
Date   Source Headline
8th Apr 20097:00 amRNSIssue of Equity
31st Mar 200910:49 amRNSTotal Voting Rights
26th Mar 20095:38 pmRNSNotification of Major Interest in Shares
26th Mar 200912:49 pmRNSResults of General Meeting
25th Mar 20099:30 amRNSNotification of Major Interest in Shares
25th Mar 20097:00 amRNSDistribution Agreement and Issue of Equity
25th Mar 20097:00 amRNSManufacturing Agreement
12th Mar 20097:00 amRNSFirst stage peptide studies
4th Mar 20094:07 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSEGM Circular
27th Feb 20093:09 pmRNSTotal Voting Rights
26th Feb 20097:00 amRNSHoldings in Company
19th Feb 20097:00 amRNSFurther issue of shares
18th Feb 20097:00 amRNSIssue of Equity and Shareholdings
30th Jan 200912:53 pmRNSTotal Voting Rights
26th Jan 200912:21 pmRNSDistribution agreement in Turkey
20th Jan 20095:03 pmRNSHolding(s) in Company
15th Jan 20091:43 pmRNSIssue of Equity
6th Jan 20093:23 pmRNSResults of General Meeting
5th Jan 20094:41 pmRNSIssue of Equity
31st Dec 20087:00 amRNSTotal Voting Rights
19th Dec 20084:22 pmRNSHolding(s) in Company
12th Dec 200810:47 amRNSNotice of EGM
9th Dec 20084:30 pmRNSIssue of Equity
8th Dec 200811:15 amRNSA Book on Zolpidem Effects Published
4th Dec 200810:13 amRNSFull Colostrinin Study Results published
28th Nov 20084:24 pmRNSTotal Voting Rights
26th Nov 20087:00 amRNSColostrinin Test marketing in Poland
25th Nov 20083:39 pmRNSIssue of Equity
24th Nov 20087:00 amRNSFocus on Colostrinin revenue generation
10th Nov 20087:00 amRNSIssue of Shares
4th Nov 20081:10 pmRNSShareholding
31st Oct 200810:56 amRNSTotal Voting Rights
27th Oct 20087:00 amRNSIssue of Equity
13th Oct 20085:19 pmRNSSignificant Shareholding
9th Oct 20083:59 pmRNSHolding(s) in Company
9th Oct 20087:00 amRNSEuropean Launch of Colostrinin in Cyprus
6th Oct 200812:51 pmRNSGeneral Meeting, Share Capital Sub-division
6th Oct 20087:00 amRNSZolpidem Review
2nd Oct 20082:03 pmRNSSignificant Shareholding
30th Sep 20083:44 pmRNSTotal Voting Rights
23rd Sep 20085:29 pmRNSHolding(s) in Company
23rd Sep 20085:21 pmRNSHolding(s) in Company
23rd Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSIssue of Equity
12th Sep 20087:00 amRNSGeneral Meeting
2nd Sep 20084:07 pmRNSTR-1 announcement
29th Aug 200812:33 pmRNSTotal Voting Rights
13th Aug 20087:00 amRNSPlacing
12th Aug 20087:00 amRNSFinancing and Commercial Upda

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.